Haldensleben, Germany Clinical Trials

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

This is a prospective, single-arm, multi-center observational non-interventional study (NIS) in Germany and Austria.